Because of lacking CD3ζ signaling, the PD-L1.BB CSR only mediates PD-L1 signal conversion rather than tumor cell killing, which can avoid PD-L1.BB CSR activation-mediated cytotoxicity on PD-L1+ immune cells. This evidence concerns the gene CD274 and neoplasm.